Loading...
•
Sep 30, 2022
Halozyme Q3 2022 Earnings Report
Halozyme's financial performance for Q3 2022 was reported, featuring significant revenue growth and advancements in partner collaborations.
Key Takeaways
Halozyme reported an 80% year-over-year increase in revenue for the third quarter of 2022, reaching $209 million. This growth was driven by increased royalty revenue, the addition of product sales from the Antares Pharma acquisition, and increased revenues from collaborative agreements. The company reiterated its 2022 revenue guidance of $655 million to $685 million, representing 48%-55% growth over 2021.
Revenue for the third quarter increased by 80% year-over-year to $209 million.
GAAP diluted earnings per share was $0.44, while non-GAAP diluted earnings per share was $0.74.
Royalty revenue for the third quarter increased by 70% year-over-year to $99.6 million.
The company reiterated its 2022 revenue guidance of $655 million to $685 million.
Halozyme
Halozyme
Halozyme Revenue by Segment
Revenue by Segment
Royalties Revenue
CapyFin.comUnder Collaborative Agreements Revenue
CapyFin.com Forward Guidance
The company reiterated its financial guidance for 2022, projecting total revenue of $655 million to $685 million, representing growth of 48% to 55% over 2021.
Positive Outlook
- Total revenue of $655 million to $685 million, representing growth of 48% to 55% over 2021
- Projected revenue contribution from the Antares business of $115 million to $125 million.
- Revenue from royalties to increase by approximately 70% over revenue from royalties in 2021, to approximately $350 million to $360 million.
- GAAP Operating income of $240 million to $265 million
- Non-GAAP diluted earnings per share are expected to be $2.10 to $2.25
Challenges Ahead
- GAAP Operating income includes one-time transaction costs of approximately $45 million and amortization of approximately $80 million related to the Antares acquisition.
- GAAP net income of $170 million to $195 million
- GAAP diluted earnings per share of $1.20 to $1.35 due to acquisition related costs in 2022.
- The Company notes that 2022 will be the first full fiscal year in which Halozyme will record income tax expense as part of its income statement.
- The Company’s earnings per share guidance does not consider the impact of potential future share repurchases.
Revenue & Expenses
Visualization of income flow from segment revenue to net income